A71.F · Ascendis Pharma A/S

-

Please sign in to comment on A71.F

1 Comment

Admin

4 years ago

Ascendis Pharma A/S is currently in a long term downtrend where the price is trading 14.1% below its 200 day moving average.

From a valuation standpoint, the stock is 39.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 800.8.

Ascendis Pharma A/S's total revenue sank by 78.7% to $535K since the same quarter in the previous year.

Its net income has dropped by 72.9% to $-139M since the same quarter in the previous year.

Finally, its free cash flow fell by 87.8% to $-95M since the same quarter in the previous year.

Based on the above factors, Ascendis Pharma A/S gets an overall score of 1/5.

Exchange	F
CurrencyCode	EUR
ISIN	US04351P1012
Sector	Healthcare
Industry	Biotechnology

Market Cap	6B
PE Ratio	None
Beta	0.55
Dividend Yield	0.0%
Target Price	193.5

ABOUT

Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/" for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

A71.F · Ascendis Pharma A/S

-

Ascendis Pharma A/S

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ascendis Pharma A/S using a moving average strategy